Have a personal or library account? Click to login
The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania) Cover

The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)

Journal of Interdisciplinary Medicine
Volume 6 (2021): Issue 3 (September 2021)
By: Nimród László,  Hédy Katalin Sárközy,  Cristina Alexandra Man,  Edith Simona Ianoși,  Botond Mátyás,  Bianca Emilia Ciurba,  Corina Mărginean and  Gabriela Jimborean  
Open Access
|Oct 2021
DOI: https://doi.org/10.2478/jim-2021-0030 | Journal eISSN: 2501-8132 | Journal ISSN: 2501-5974
Journal RSS Feed
Language: English
Page range: 157 - 161
Submitted on: Sep 4, 2021
Accepted on: Sep 11, 2021
Published on: Oct 14, 2021
Published by: Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
monoclonal antibody therapy,
severe eosinophilic asthma,
clinical parameters,
eosinophils
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other,
Internal medicine,
Internal medicine, other,
Surgery,
Surgery, other,
Emergency medicine and intensive-care medicine

© 2021 Nimród László, Hédy Katalin Sárközy, Cristina Alexandra Man, Edith Simona Ianoși, Botond Mátyás, Bianca Emilia Ciurba, Corina Mărginean, Gabriela Jimborean, published by Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 6 (2021): Issue 3 (September 2021)Next article